Polyphenol (-)-epigallocatechin gallate targeting myocardial reperfusion limits infarct size and improves cardiac function

Korean Journal of Anesthesiology

Volumn 58, Issue 2, 2010, Pages 169-175

  Kim, Chan Jin ^a   Kim, Jin Mo ^a   Lee, Seung Ryong ^a   Jang, Young Ho ^b,c   Kim, June Hong ^c   Chun, Kook Jin ^c  

^a Keimyung University   (South Korea)

^b Pureun Hospital   (South Korea)

^c Pusan National University Hospital   (South Korea)

Author keywords

( ) Epigallocatechin gallate; Green tea; Myocardium; Reperfusion injury

Indexed keywords

EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; TRIPHENYLTETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY REPERFUSION; DRUG EFFECT; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION SIZE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART MUSCLE REPERFUSION; HEART PROTECTION; MALE; MORPHOMETRICS; NONHUMAN; RAT; REPERFUSION INJURY;

EID: 77953373274     PISSN: 20056419     EISSN: 20057563     Source Type: Journal    
DOI: 10.4097/kjae.2010.58.2.169     Document Type: Article

References (28)

1. Zhang A, Zhu QY, Luk YS, Ho KY, Fung KP, Chen ZY. Inhibitory effects of jasmine green tea epicatechin isomers on free radical-induced lysis of red blood cells. Life Sci 1997; 61: 383-94.
2. Mabe K, Yamada M, Oguni I, Takahashi T. In vitro and in vivo activities of tea catechins against Helicobacter pylori. Antimicrob Agents Chemother 1999; 43: 1788-91.
3. Han MK. Epigallocatechin gallate, a constituent of green tea, suppresses cytokine-induced pancreatic beta-cell damage. Exp Mol Med 2003; 35: 136-9.
4. Hara S, Endo T, Kuriiwa F, Kano S. NADPH-dependent reaction of paraquat in mouse brain microsomes. Toxicol Lett 1990; 54: 271-7.
5. Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002; 42: 25-54.
6. Lim DY, Lee ES, Park HG, Kim BC, Hong SP, Lee EB. Comparison of green tea extract and epigallocatechin gallate on blood pressure and contractile responses of vascular smooth muscle of rats. Arch Pharm Res 2003; 26: 214-23.
7. Miura Y, Chiba T, Tomita H, Koizumi H, Miura S, Umegaki K. Tea catechins prevent the development of atherosclerosis in apoprotein E-deficient mice. J Nutr 2001; 131: 27-32.
8. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993; 342: 1007-11.
9. Jin JY, Park SH, Bae JH, Cho HC, Lim JG, Park WS. Uncoupling by (-)-epigallocatechin-3-gallate of ATP-sensitive potassium channels from phosphatidylinositol polyphosphates and ATP. Pharmacol Res 2007; 56: 237-47.
10. Park JW, Jang YH, Kim JM, Lee H, Park WK, Lim MB. Green tea polyphenol (-)-epigallocatechin gallate reduces neuronal cell damage and up-regulation of MMP-9 activity in hippocampal CA1 and CA2 areas following transient global cerebral ischemia. J Neurosci Res 2009; 87: 567-75.
11. Jang YH, Lee YC, Park NH, Shin HY, Mun KC, Choi MS. Polyphenol (-)-epigallocatechin gallate protection from ischemia/reperfusion-induced renal injury in normotensive and hypertensive rats. Transplant Proc 2006; 38: 2190-4.
12. Townsend PA, Scarabelli TM, Pasini E, Gitti G, Menegazzi M, Suzuki H. Epigallocatechin-3-gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/reperfusion-induced apoptosis. FASEB J 2004; 18: 1621-3.
13. Aneja R, Hake PW, Burroughs TJ, Denenberg AG, Wong HR, Zingarelli B. Epigallocatechin, a green tea polyphenol, attenuates myocardial ischemia reperfusion injury in rats. Mol Med 2004; 10: 55-62.
14. Lee YC, Jang YH, Kim JM, Kim AR, Kim CJ, Kim YN. Effect of a kappa-opioid receptor agonist U50488H given at early reperfusion phase in isolated rat hearts. Korean J Anesthesiol 2008; 54: S29-34.
15. Li D, Yang C, Chen Y, Tian J, Liu L, Dai Q. Identification of a PKCepsilon-dependent regulation of myocardial contraction by epicatechin-3-gallate. Am J Physiol Heart Circ Physiol 2008; 294: H345-53.
16. Hirai M, Hotta Y, Ishikawa N, Wakida Y, Fukuzawa Y, Isobe F. Protective effects of EGCg or GCg, a green tea catechin epimer, against postischemic myocardial dysfunction in guinea-pig hearts. Life Sci 2007; 80: 1020-32.
17. Lochner A, Genade S, Moolman JA. Ischemic preconditioning: infarct size is a more reliable endpoint than functional recovery. Basic Res Cardiol 2003; 98: 337-46.
18. Nakachi K, Matsuyama S, Miyake S, Suganuma M, Imai K. Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors 2000; 13: 49-54.
19. Sano J, Inami S, Seimiya K, Ohba T, Sakai S, Takano T. Effects of green tea intake on the development of coronary artery disease. Circ J 2004; 68: 665-70.
20. Kuriyama S. The relation between green tea consumption and cardiovascular disease as evidenced by epidemiological studies. J Nutr 2008; 138: 1548S-1553S.
21. Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, Nishino Y. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 2006; 296: 1255-65.
22. Potenza MA, Marasciulo FL, Targuinio M, Tiravanti E, Colantuono G, Federici A. EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab 2007; 292: E1378-87.
23. Xi JK, Jin YZ, Cui X, Xu Z. Cardioprotection against reperfusion injury: updated mechanisms and strategies. Sheng Li Xue Bao 2007; 59: 553-61.
24. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 2005; 15: 69-75.
25. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 2006; 70: 240-53.
26. Dreger H, Lorenz M, Kehrer A, Baumann G, Stangl K, Stangl V. Characteristics of catechin- and theaflavin-mediated cardioprotection. Exp Biol Med (Maywood) 2008; 233: 427-33.
27. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 2002; 55: 534-43.
28. Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 2003; 35: 339-41.